~~<i id='855F6FF4A9'><strike id='855F6FF4A9'><tt id='855F6FF4A9'><pre id='855F6FF4A9'></pre></tt></strike></i>~~

00:00

00:00 00:00 LIVE

buffering

Replay

knowledge

author：comprehensive 2025-09-30 22:27:42 - browse：7675

The FDA building -- First Opinion coverage from STAT — Adobe

The Food and Drug Administration on Thursday approved the first medicine developed specifically to treat the serious liver disease known as MASH.

The pill, called Rezdiffra, is made by Madrigal Pharmaceuticals.

Metabolic dysfunction-associated steatohepatitis, or MASH, is often associated with obesity. The accumulation of fat in the liver causes inflammation, which leads to fibrosis, or liver scarring, and can progress in more advanced stages to cirrhosis, cancer, and the need for a liver transplant.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Affirmative action in medical school literally saved lives
Next article： When women are denied an abortion, their children fare worse than peers

hotspot

knowledge

entertainment

leisure time

focus

entertainment

AdobeWILMINGTON,Del.—Wednesdaywasthefirsttimethatafederaljudgeaskedquestionsin-personofdrugindustryl

WSS

Histogen: Failed biotech offers rare public look inside

10 reasons why health care startups fail

Merck CEO won’t testify in Senate, citing no expertise in drug prices

Boston competes with Raleigh

A virus, fished out of a lake, may have saved a man’s life

A Q&A with the global head of Boehringer Ingelheim's innovation unit

knowledge

knowledge

hotspot

Jerome Adams on the need for new antivirals for Covid

Boston competes with Raleigh

Trump demands the U.S. pay no more for drugs than other countries … again

Biogen walks away from Aduhelm, years after polarizing approval

Medicare proposal to cover medical devices draws a mixed reaction

Bristol 'take

BioMarin wins approval for gene therapy to treat hemophilia A

Humana’s losses in Medicare Advantage tank its stock

Hollywood unions extend contract negotiations for actors

Syphilis numbers in the United States reach record heights

knowledge

Biogen walks away from Aduhelm, years after polarizing approval

The latest on Bluebird gene therapies, Vertex's pain drug, and ADC FOMO

Physician executives need more than on

Physician executives need more than on

FTC sues over Novant Health acquisition of two N.C. hospitals

The future of health care in the House

entertainment

leisure time

focus

entertainment